Type Condition

Cullman, AL

203 Clinical Trials near Cullman, AL

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Amivantamab Combinations for Non-Small Cell Lung Cancer

Huntsville, Alabama
The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

365 Participants Needed

MEDI0618 for Migraine

Huntsville, Alabama
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

12 Participants Needed

BAY3283142 for Chronic Kidney Disease

Huntsville, Alabama
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the urine. This condition is known as albuminuria. This can lead to a faster decline in kidney function. People who have high blood pressure and diabetes are more likely to have CKD and are at a higher risk of complications related to it. BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD. In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD. They will compare the results of the change in the urine albumin-creatinine ratio (UACR) after 16 weeks for BAY3283142 with a placebo. A placebo looks like the study drug but does not have any medicine in it. During the study, participants will take either of the following drugs: * BAY3283142: Participants will take BAY3283142 as tablets by mouth. * Placebo: Participants will take it in the same way as BAY3283142. Participants will continue taking the available standard treatment for CKD and other conditions they may have (for example, heart conditions and diabetes). At the start of this study, the researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR. Participants will be divided equally into different groups. Only 1 group will receive placebo and the other groups will receive BAY3283142. Participants will take their assigned treatment for 16 weeks. No one will know who receives which drug or dose of BAY3283142 during the study. Participants will be in this study for around 23 weeks. This includes the time for screening before the start of treatment and follow-up with participants after treatment. People can join this study if they: * are 18 years of age or older and have been diagnosed with CKD * have poor kidney function according to the eGFR test * have abnormally high levels of albumin in the urine according to the UACR test * have been taking certain drugs at a stable dose for management of high blood pressure, diabetes, kidney disease, etc. for at least 4 weeks before the start of the study People cannot join this study if they: * have low blood pressure * have had a stroke or a heart attack, or were hospitalized because of heart failure in the 3 months before the start of the study * have a serious liver disease * have a kidney disease for which they need to take drugs that control the immune system The detailed requirements will be discussed between the study doctors and people considering joining this study. Participants may or may not get the expected benefits of treatment with BAY3283142, but they will receive thorough medical check-ups during this study. These can help to improve individual treatment in the future and to identify unknown medical risks. Some participants may experience medical problems during this study including pain and discomfort when blood samples are taken. Researchers will closely monitor and manage any medical problems the participants may have. They will not include people who should not take BAY3283142 due to known safety concerns. The findings from this study may contribute to developing a new treatment option for people with CKD who have excess albumin in the urine.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

700 Participants Needed

JK07 for Heart Failure

Huntsville, Alabama
This trial is testing a new medication called JK07 in people aged 18-85 who have heart failure. The study includes two groups based on how well their heart is pumping. Participants will receive either a low dose or high dose of JK07. The goal is to see if JK07 can improve heart function and help these patients feel better.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

282 Participants Needed

TOUR006 for Chronic Kidney Disease

Huntsville, Alabama
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

143 Participants Needed

Zilebesiran for High Blood Pressure

Huntsville, Alabama
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

375 Participants Needed

CIN-103 for Irritable Bowel Syndrome

Huntsville, Alabama
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the following visits: * Screening Period (1 Visit) * Baseline Period (1 Visit) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued participation. * 12-Week Treatment Period (5 Visits) * Study drug taken twice daily by mouth. * Will complete daily diaries and other PROs as described in the protocol. * Follow- Up Period (1 Visit) Researchers will compare CIN-103 Dose 1, CIN-103 Dose 2, and placebo, to evaluate the clinical response to multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency along with safety and tolerability.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

450 Participants Needed

RSV mRNA Vaccine for Respiratory Syncytial Virus Immunization

Huntsville, Alabama
This trial tests a new RSV vaccine that uses tiny fat particles to help deliver it into the body. It aims to see if the vaccine is safe and effective in healthy adults aged 18-50 and those aged 60 and older. The vaccine works by teaching the immune system to recognize and fight RSV.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

865 Participants Needed

Rencofilstat for NASH with Advanced Liver Fibrosis

Huntsville, Alabama
This trial tests Rencofilstat, a medication that may improve liver damage, in adults with NASH and significant liver fibrosis. The drug works by reducing liver scarring and damage.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

120 Participants Needed

Oral Azacitidine for Acute Myeloid Leukemia

Huntsville, Alabama
The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute Myeloid Leukemia (AML) and in complete remission/complete remission with incomplete blood count recovery after conventional induction chemotherapy with or without consolidation chemotherapy.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55+

19 Participants Needed

Abelacimab vs. Rivaroxaban for Atrial Fibrillation

Huntsville, Alabama
This trial is testing a new blood thinner called abelacimab to see if it causes less bleeding compared to an existing drug, rivaroxaban. It focuses on patients with atrial fibrillation who are at a higher risk of stroke. Blood thinners help prevent strokes by stopping clots, but they can also cause bleeding.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55+

1287 Participants Needed

HM15211 for Non-alcoholic Steatohepatitis (NASH)

Huntsville, Alabama
This trial is testing a medication called HM15211 to see if it can help people with a liver disease called NASH. The study will check if the medication is safe and effective over a period of time.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

240 Participants Needed

Zanubrutinib for Lymphoma

Huntsville, Alabama
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

90 Participants Needed

Nivolumab Safety for Cancer

Huntsville, Alabama
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

1500 Participants Needed

BRTX-100 for Chronic Lumbar Disc Disease

Birmingham, Alabama
This is a double-blind, saline-controlled, and randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 60

99 Participants Needed

Zelquistinel for Depression

Huntsville, Alabama
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64

164 Participants Needed

Niagen®+ for Healthy Aging

Huntsville, Alabama
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:40 - 65

70 Participants Needed

Ashwagandha Extract for Stress

Huntsville, Alabama
The purpose of this study is to evaluate the efficacy of two proprietary ashwagandha extracts on stress levels, with secondary outcomes of cognition, energy, and sleep, as compared to a placebo.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30 - 59
Sex:Female

60 Participants Needed

Metrix Test for COVID-19 and Flu

Trussville, Alabama
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID/Flu Test for the differential detection of SARS-CoV-2, Influenza A, and Influenza B in AN swab or saliva samples. Additional sites may be added to the study in order to meet minimum subject/sample enrollment requirements and geographic prevalence of respiratory virus infections. One or more investigational sites outside of the US (at which participants are required to be fluent in English) may also be included in the study depending on enrollment needs and geographical/seasonal prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Flu A, and/or Flu B.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:2+

1000 Participants Needed

Shockwave Therapy for Coronary Artery Disease

Huntsville, Alabama
This investigational device exemption (IDE) study is to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary lesions prior to stenting.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

145 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

Ear Tube Insertion Device for Ear Infections

Huntsville, Alabama
This trial is testing a device that helps doctors put small tubes in children's eardrums. It targets kids who need this procedure to prevent ear infections. The device works by making it easier to place the tubes, which help drain fluid from the ear.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 13

66 Participants Needed

Left Atrial Appendage Exclusion for Stroke Prevention

Huntsville, Alabama
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6500 Participants Needed

Cognitive Behavioral Therapy for Alcohol Use Disorder in HIV

Huntsville, Alabama
This study is designed to examine the efficacy of a brief intervention plus a cognitive-behavioral intervention compared to brief intervention alone to address unhealthy alcohol use and comorbid mental health symptoms to improve HIV outcomes among people living with HIV in Alabama.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

308 Participants Needed

Endoscopic Airway Examination for Predicting Intubation Complications

Birmingham, Alabama
Purpose of study: To contrast and compare the Mallampatti test to a comprehensive airway grading test using a rigid 75-degree angle laryngoscope (CPAG) Study Hypothesis: The investigators hypothesize that the CPAG will have greater sensitivity and specificity for predicting difficulty laryngoscopy as compared to the Mallampati test. The investigators plan to test this hypothesis by comparing the correlation of (a) airway Mallampati airway grading (predicted airway difficulty) versus (b) CPAG view grading and Cormack Laryngoscopy assessment (observed airway difficulty).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

200 Participants Needed

Defibrillator Lead for Rapid Heartbeat

Huntsville, Alabama
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:12+

998 Participants Needed

AGN1 LOEP SV Kit for VCFs

Birmingham, Alabama
This trial is testing a new device called the AGN1 LOEP SV Kit for patients with painful spinal fractures. The device works by stabilizing the broken bone in the spine to reduce pain.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 85

408 Participants Needed

Left Atrial Appendage Occlusion vs. NOAC for Atrial Fibrillation

Huntsville, Alabama
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2650 Participants Needed

VNS for Bipolar Depression

Huntsville, Alabama
This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

6800 Participants Needed

Biofeedback + Injection for Bowel Incontinence

Birmingham, Alabama
This trial is for patients with severe fecal incontinence who haven't responded to initial treatments. It compares two methods: muscle training and a treatment that adds bulk to the rectum. The goal is to see which method better reduces incontinence episodes.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

275 Participants Needed

WiSE CRT System for Heart Failure

Huntsville, Alabama
This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

300 Participants Needed

1...4567

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Cullman, AL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Cullman, AL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Cullman, AL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Cullman, AL is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Cullman, AL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Cullman, AL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Cullman, AL?

Most recently, we added Nerandomilast for Interstitial Lung Disease, Oral Tranexamic Acid for Shoulder Replacement Surgery and Vicadrostat + Empagliflozin for Chronic Kidney Disease to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards in Cullman, AL?

The clinics in Cullman, AL currently recognized as SuperSites are: University of Alabama at Birmingham in Birmingham, Alabama

Popular Searches

By Condition

Depression Clinical Trials in Alabama

Anxiety Clinical Trials in Alabama

Schizophrenia Clinical Trials in Alabama

ADHD Clinical Trials in Alabama

Bipolar Disorder Clinical Trials in Alabama

Multiple Sclerosis Clinical Trials in Alabama

Autism Clinical Trials in Alabama

Treatment Resistant Depression Clinical Trials in Alabama

Borderline Personality Disorder Clinical Trials in Alabama

Social Anxiety Disorder Clinical Trials in Alabama

Parkinson's Disease Clinical Trials in Alabama

Alzheimer's Disease Clinical Trials in Alabama

By Location

Clinical Trials near Birmingham, AL

Clinical Trials near Mobile, AL

Clinical Trials near Huntsville, AL

Clinical Trials near Anniston, AL

Clinical Trials near Dothan, AL

Clinical Trials near Montgomery, AL

Clinical Trials near Tuscaloosa, AL

Clinical Trials near Homewood, AL

Clinical Trials near Cullman, AL

Clinical Trials near Muscle Shoals, AL

Clinical Trials near Jasper, AL

Clinical Trials near Sheffield, AL

Other People Viewed

By Subject

Top Clinical Trials near Jasper, AL

Top Clinical Trials near Homewood, AL

Top Clinical Trials near Hueytown, AL

Top Clinical Trials near Haleyville, AL

Top Clinical Trials near Fairhope, AL

Top Clinical Trials near Foley, AL

Top Clinical Trials near Dothan, AL

Top Clinical Trials near Daphne, AL

Top Clinical Trials near Columbiana, AL

Top Clinical Trials near Andalusia, AL

Top Clinical Trials near Anniston, AL

Top Clinical Trials near Gulf Shores, AL

By Trial

Financial Incentives + Communication Training for HPV Vaccine Uptake

HPV Self-Collection for Cervical Cancer Prevention

Celecoxib for Pain After Parotidectomy

Moodivate App for Depression in Cancer Survivors

Enhanced Support for Cardiac Rehabilitation

Oral LOXO-305 for Chronic Lymphocytic Leukemia

Exercise Programs for Limited Mobility

High-Intensity Interval Training for Parkinson's Disease

Mobile Health Interventions for Medication Adherence

Virtual Seated Exercises for Stroke

Ketogenic Diet for Cardiovascular Health

Tart Cherry Concentrate for Post-Operative Atrial Fibrillation

Related Searches

Top Clinical Trials near Cutler Bay, FL

Top Clinical Trials near Cypress, TX

Androgen Receptor Therapies for Prostate Cancer

SBT777101 for Rheumatoid Arthritis

Trial Enrollment Diversity Dashboard for Leukemia

Green Tea, Quercetin + Chemotherapy for Prostate Cancer

Implanted Loop Recorder for Arrhythmia Detection

Influenza Vaccine for Flu

NICOM for Septic Shock

Top Clinical Trials near West Virginia

Nivolumab + Cabozantinib for Melanoma

Top Clinical Trials near Greenbelt, MD

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial